Filing Flows › Sight Sciences (SGHT) › Q2 2025
Sight Sciences (SGHT) Q2 2025 earnings results (second quarter 2025)
10-Q filed Aug 7, 2025
Sight Sciences (SGHT) reported revenue of $19.6M for the second quarter 2025 (Q2 2025), -8% from a year earlier and +12% from the quarter before. Operating margin was -59.6%, net loss $11.9M (61.0% of revenue).
Sight Sciences, Q2 2025: revenue $19.6M (-8% year over year), operating margin -59.6%, net loss $11.9M, operating cash flow −$7.5M. The chart follows the revenue to costs, profit and cash.
| Q2 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $19.6M | +12% | -8% |
| Operating profit | −$11.7M | — | — |
| Net earnings | −$11.9M | — | — |
| Operating cash flow | −$7.5M | — | — |
What changed
Revenue was $19.6M in Q2 2025, down 8% year over year and up 12% from the previous quarter. Surgical Glaucoma was the largest line at 98% of revenue. Surgical Glaucoma lost $1.0M year over year (down 5%), 56% of the total change.
Gross margin was 84.8%, down 1.1 points from a year earlier. Operating costs exceeded revenue by $11.7M, an operating margin of -59.6%. Operating expenses fell 9% while revenue fell 8%. The quarter ended with a net loss of $11.9M, narrower than the previous quarter's $14.2M loss.
Operating cash flow was −$7.5M. Non-cash charges added back $125K of depreciation and amortization and $3.8M of share-based compensation. Working capital and other items added $431K. Capital expenditures of $210K exceeded it, leaving free cash flow of −$7.8M.
Questions
What was Sight Sciences' revenue in the second quarter 2025?
Sight Sciences (SGHT) reported revenue of $19.6M for the second quarter 2025 (Q2 2025), -8% from a year earlier and +12% from the quarter before.
Was Sight Sciences profitable in the second quarter 2025?
Operating loss was $11.7M (-59.6% of revenue) and net loss $11.9M.
Source: Sight Sciences 10-Q on SEC EDGAR.